PURE Bioscience, Inc. PURE
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -13.61% | 3.05% | 13.55% | 27.34% | 61.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.61% | 3.05% | 13.55% | 27.34% | 61.18% |
| Cost of Revenue | -1.69% | 13.94% | 25.61% | 11.69% | 48.74% |
| Gross Profit | -21.15% | -4.95% | 4.85% | 38.46% | 70.18% |
| SG&A Expenses | 6.57% | -8.76% | -2.76% | -15.66% | -13.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.73% | -4.74% | 0.99% | -8.11% | -1.17% |
| Operating Income | -49.70% | 11.30% | 5.79% | 39.55% | 47.42% |
| Income Before Tax | -83.73% | -7.59% | 1.63% | 32.66% | 56.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.73% | -7.59% | 1.63% | 32.66% | 56.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.73% | -7.59% | 1.63% | 32.66% | 56.08% |
| EBIT | -49.70% | 11.30% | 5.79% | 39.55% | 47.42% |
| EBITDA | -49.40% | 11.15% | 5.87% | 35.93% | 44.09% |
| EPS Basic | -53.33% | -7.69% | 1.41% | 33.87% | 55.88% |
| Normalized Basic EPS | -107.14% | 5.41% | 2.22% | 31.58% | 64.10% |
| EPS Diluted | -53.33% | -7.69% | 1.41% | 33.87% | 55.88% |
| Normalized Diluted EPS | -107.14% | 5.41% | 2.22% | 31.58% | 64.10% |
| Average Basic Shares Outstanding | 17.26% | -0.92% | 0.03% | 0.03% | 0.02% |
| Average Diluted Shares Outstanding | 17.26% | -0.92% | 0.03% | 0.03% | 0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |